[A18-56] Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28
|Commission:||Commission awarded on 2018-09-11 by the Federal Joint Committee (G-BA)|
|Current document:||Addendum to Commission A18-28 (German version) Further documents|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Contact address:||to the contact form|
Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
|2018-11-07||Addendum to Commission A18-28 (German version)||123 kB|
Federal Joint Committee (G-BA)
2018-11-07 A G-BA decision was published.